Moreover, the blockade of IL-17A with monoclonal antibodies (anti-IL-17A) in psoriasis, PsA, and AS has proven to be a highly effective therapeutic approach [[4], [5], [6], [7], [8], [9], [10], [11]]. The gene discussed is IL17A; the disease is psoriasis.